Temozolomide chemotherapy in recurrent oligodendroglioma

被引：63

作者：

van den Bent, MJ

Keime-Guibert, F

Brandes, AA

Taphoorn, MJB

Kros, JM

Eskens, FALM

Carpentier, AF

机构：

[1] Univ Rotterdam Hosp, Rotterdam Canc Ctr, Dept Neurooncol, NL-3008 AE Rotterdam, Netherlands

[2] Univ Rotterdam Hosp, Rotterdam Canc Ctr, Dept Pathol, NL-3008 AE Rotterdam, Netherlands

[3] Univ Rotterdam Hosp, Rotterdam Canc Ctr, Dept Oncol, NL-3008 AE Rotterdam, Netherlands

[4] Hop La Pitie Salpetriere, Federat Neurol Marazin, Paris, France

[5] Univ Padua, Azienda Osped, Div Med Oncol, I-35100 Padua, Italy

[6] Univ Med Ctr Utrecht, Dept Neurol, Utrecht, Netherlands

来源：

NEUROLOGY | 2001年 / 57卷 / 02期

关键词：

D O I：

10.1212/WNL.57.2.340

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m(2) on days 1 through 5 in cycles of 28 days. Nine patients responded: 7 of 27 patients (26%) treated with temozolomide after prior PCV chemotherapy and 2 of 3 chemotherapy-naive patients (both complete response). Median time to progression in responding patients was 13 months. Temozolomide shows promise and has an acceptable safety profile in recurrent anaplastic oligodendroglial tumors. Patients not responding to PCV may respond to temozolomide.

引用

页码：340 / 342

页数：3

共 11 条

[1] CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA [J].

CAIRNCROSS, G ;

MACDONALD, D ;

LUDWIN, S ;

LEE, D ;

CASCINO, T ;

BUCKNER, J ;

FULTON, D ;

DROPCHO, E ;

STEWART, D ;

SCHOLD, C ;

WAINMAN, N ;

EISENHAUER, E .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2013-2021

[2] Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].

Cairncross, JG ;

Ueki, K ;

Zlatescu, MC ;

Lisle, DK ;

Finkelstein, DM ;

Hammond, RR ;

Silver, JS ;

Stark, PC ;

Macdonald, DR ;

Ino, Y ;

Ramsay, DA ;

Louis, DN .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479

[3] Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas [J].

Chamberlain, MC ;

Kormanik, PA .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (12) :3427-3432

[4]

Coons SW, 1997, CANCER, V79, P1381, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO

[5]

2-W

[6]

Fulton D, 1996, J NEURO-ONCOL, V27, P149

[7] Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma [J].

Paleologos, NA ;

Macdonald, DR ;

Vick, NA ;

Cairncross, JG .

NEUROLOGY, 1999, 53 (05) :1141-1143

[8] Salvage chemotherapy for oligodendroglioma [J].

Peterson, K ;

Paleologos, N ;

Forsyth, P ;

Macdonald, DR ;

Cairncross, JG .

JOURNAL OF NEUROSURGERY, 1996, 85 (04) :597-601

[9]

SOFFIETTI R, 1996, J NEUROONCOL, V30, P153

[10] Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy [J].

van den Bent, MJ ;

Kros, JM ;

Heimans, JJ ;

Pronk, LC ;

van Groeningen, CJ ;

Krouwer, HGJ ;

Taphoorn, MJB ;

Zonnenberg, BA ;

Tijssen, CC ;

Twijnstra, A ;

Punt, CJA ;

Boogerd, W .

NEUROLOGY, 1998, 51 (04) :1140-1145

← 1 2 →